PROM1 and cancer: Based on our studies, it should be clarified how the PD-L1+ CD49+ CD133+ CTC phenotype associated with poor clinical outcome develops during carcinogenesis within the tumormicromilieu, survives cancer therapies and can be systemically sustained potentially supported by the therapy-induced systemic cellular or soluble milieu.